<DOC>
	<DOCNO>NCT02730169</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy BGS649 male obese subject hypogonadotrophic hypogonadism . All subject treat maximum 24 week . Some subject complete 24 week treatment invited participate 6-month blind safety extension study ( Protocol MBGS206 ) . The study plan enroll 268 subject .</brief_summary>
	<brief_title>Safety Efficacy BGS649 Male Obese Subjects With Hypogonadotrophic Hypogonadism</brief_title>
	<detailed_description />
	<mesh_term>Hypogonadism</mesh_term>
	<criteria>Adult male subject age 18 65 year inclusive BMI &gt; 30 kg/m2 &lt; 50 kg/m2 Serum total testosterone concentration normal range LH level upper limit normal Oestradiol level within normal range approve assay At least two symptom androgen deficiency present least 2 month prior first Screening Visit , least one sexual dysfunction Evidence clinically significant endocrinopathy screening may interfere study assessment Other type hypogonadotrophic hypogonadism primary hypogonadism Any pituitary hypothalamic disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hypogonadotropic</keyword>
	<keyword>hypogonadism</keyword>
	<keyword>testosterone</keyword>
</DOC>